Compare GWW & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWW | ARGX |
|---|---|---|
| Founded | 1927 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6B | 52.0B |
| IPO Year | 1994 | 2017 |
| Metric | GWW | ARGX |
|---|---|---|
| Price | $1,111.46 | $721.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | ★ $1,086.43 | $991.56 |
| AVG Volume (30 Days) | 254.7K | ★ 324.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 35.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.59 | $40.84 |
| Revenue Next Year | $6.67 | $22.38 |
| P/E Ratio | ★ $32.37 | $33.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $893.99 | $510.06 |
| 52 Week High | $1,218.63 | $934.62 |
| Indicator | GWW | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 25.32 |
| Support Level | $1,099.21 | $698.92 |
| Resistance Level | $1,218.63 | $856.67 |
| Average True Range (ATR) | 25.97 | 20.42 |
| MACD | -4.60 | -11.00 |
| Stochastic Oscillator | 16.33 | 10.36 |
Founded in 1927, W.W. Grainger originally distributed various motors via a mail-order catalogue. Over the course of the 20th century, the firm expanded into new industrial product categories and launched its first digital catalogue in 1995. Today, the company organizes itself into two segments focused on different customer bases. Its larger segment, high-touch solutions, offers a vast array of maintenance, repair, and operations, or MRO, supplies and bespoke inventory management services to larger businesses. Its smaller segment, endless assortment, operates two online platforms, Zoro and MonotaRO, that offer comprehensive catalogues of MRO supplies to smaller businesses. Grainger has operations throughout the world but primarily generates sales within the US.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.